Who is sponsoring NCT03730519?

NCT03730519 is sponsored by Queen Mary University of London.

What drugs are being tested in NCT03730519?

Interventions in NCT03730519: Baroreflex Activation Therapy with Barostim Neo.

What condition does NCT03730519 study?

NCT03730519 studies Baroreflex Failure Syndrome, Hypertension, Resistant to Conventional Therapy.

Is NCT03730519 still recruiting?

NCT03730519 is currently terminated. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT03730519: UK-BAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UK Registry for Baroreflex Activation Therapy

Terminated NA Last updated 8 June 2023

What this trial tests

NA trial testing Baroreflex Activation Therapy with Barostim Neo in Baroreflex Failure Syndrome in 6 participants. Terminated before completion.

Timeline

1 November 2018

Primary endpoint
1 November 2021

1 November 2021

Quick facts

Lead sponsor	Queen Mary University of London
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 November 2018
Primary completion	1 November 2021
Estimated completion	1 November 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Baroreflex Activation Therapy with Barostim Neo

Conditions studied

Baroreflex Failure Syndrome — all drugs for Baroreflex Failure Syndrome →
Hypertension, Resistant to Conventional Therapy — all drugs for Hypertension, Resistant to Conventional Therapy →

Sponsor

Queen Mary University of London

Who can join

Adults 18 to 80, any sex, with Baroreflex Failure Syndrome or Hypertension, Resistant to Conventional Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a post-marketing open label single arm, single centre clinical trial of electrical carotid sinus stimulation with the Barostim Neo device to target sub-optimally controlled arterial hypertension or highly variable blood pressure in patients for whom no alternative therapies are available.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of therapeutic lifestyle changes in resistant hypertension.
Ozemek C, Tiwari S, Sabbahi A, Carbone S, et al · · 2020 · cited 67× · PMID 31756356 · DOI 10.1016/j.pcad.2019.11.012
Implant-Mediated Therapy of Arterial Hypertension.
Gierthmuehlen M, Plachta DTT, Zentner J. · · 2020 · cited 10× · PMID 32030509 · DOI 10.1007/s11906-020-1019-7
Alleviating Hypertension by Selectively Targeting Angiotensin Receptor-Expressing Vagal Sensory Neurons.
Baumer-Harrison C, Elsaafien K, Johnson DN, Peñaloza Aponte JD, et al · · 2024 · cited 9× · PMID 38242697 · DOI 10.1523/jneurosci.1154-23.2023
Neuromodulatory Approaches for Atrial Fibrillation Ablation.
Rodríguez-Mañero M, Martínez-Sande JL, García-Seara J, González-Ferrero T, et al · · 2021 · cited 1× · PMID 35024055 · DOI 10.15420/ecr.2021.05

Verify or expand the search:

Other Queen Mary University of London trials

Trials by the same sponsor.

NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03730519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03730519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing